What I find interesting is that repurposed drugs don’t seem to reflect their true risk adjusted value compared to a new drug for ASX biotechs.
source https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-08272-z
It seems the ASX only recognises the value once P2/P3 data is available. Should we expect Race to be any different?
source https://theconversation.com/90-of-drugs-fail-clinical-trials-heres-one-way-researchers-can-select-better-drug-candidates-174152
Even Race’s own analyst reports indicate 32% probability of success in AML where Bisantrene had already been approved. Just food for thought, what is an appropriate way to rNPV a repurposed drug, v. How the market actually values it?
source https://storage.googleapis.com/leaf-prod/uploads/company_profile/61/interactions_media_update_attachments/a939d7e5-91dc-4488-8419-4575f19f6b27.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |